晚期肺癌的主要不良心血管事件:一个多中心队列研究
Chih-Hao Chang1,2,3, Shih-Hao Huang1,2,4, Hung-Yu Huang1,2,4
1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan.
Therapeutic advances in medical oncology
|January 22, 2024
概括
重大心血管不良事件 (MACE) 在接受一线表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 或化疗的晚期肺癌患者中同样发生. 然而,EGFR-TKI治疗与缺血性中风的风险更高有关.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺癌是全球主要的死亡原因之一.
- 心血管事件是癌症治疗期间已知的并发症.
- 表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 和基于的化疗是晚期肺癌的标准一线治疗方法.
研究的目的:
- 研究在接受一线向治疗与化疗的晚期肺癌患者中主要心血管不良事件 (MACE) 的发生率.
- 为了比较这些治疗组之间的特定心血管事件的风险,如缺血性中风.
主要方法:
- 使用来自光研究数据库 (CGRD) 的真实世界数据的回顾性队列研究.
- 纳入标准:在2011年1月至2017年12月期间被诊断患有晚期肺癌的患者.
- 收集的数据包括基线特征,临床阶段,病理和治疗结果.
主要成果:
- 总共分析了4406名患者:2197人接受了第一线EGFR-TKI治疗,2209人接受了第一线基于的化疗.
- 在EGFR-TKI和化疗组之间,MACE的总体发病率是可比的 (12.0%对11.9%,p=0.910).
- 与化疗组相比,EGFR-TKI组中缺血性中风的发生率明显高 (3.9%对1.9%,p<0.001).
结论:
- 在治疗期间,MACE在晚期肺癌患者中很常见,EGFR-TKI和化疗之间的总体发病率相似.
- 尽管MACE总体发生率相似,但一线EGFR-TKI治疗与一线化疗相比,与缺血性中风的风险增加有关.
- 患者人口统计学,如吸烟状况和性别,在各组之间存在差异,但在EGFR-TKI治疗时,缺血性中风的风险仍然较高.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
166
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
166
01:20COPD: Pathogenesis and Clinical Features
275
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
275
01:26COPD: Management Using Bronchodilators and Corticosteroids
208
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
208
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341